EL
Insider
EcoR1 Capital, LLC
DirectorEcoR1 Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in ZYME. Across 2 priced purchase filings, the average 21-session return was +2.8% from execution and -5.0% from disclosure (delay-adjusted; derived). The largest single filing was $40.0M of AKTS (2,222,222 sh across 2 lots, as filed), executed Jan 12.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+2.8%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-5.0%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$44.7M
shares × price, as filed
Last traded
May 7
Filed May 11
Median ADV $8.9M across their filed names
Impact on $10,000 · 12M
$8,773 (-12.3%)
S&P 500 $11,725 (+17.2%) · 29.5 pts behind
EcoR1 Capital, LLC
S&P 500
Compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $125.6M
Sells $66.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
ZYME
ZYME
ZYME · 12 buys · 0 sells
12 filings
ADAP
ADAP
ADAP · 0 buys · 1 sell
1 filing
AKTSRecent filings
ZYMEPURCHASE
Zymeworks Inc.
View filing →
$1.9M130,309 sh across 3 lots
Exec Dec 24 2024
Filed Dec 27 2024 · 5:30 PM ET ZYMEPURCHASE Zymeworks Inc. View filing → $17.5M
1,254,808 sh across 3 lots
Exec Dec 19 2024
Filed Dec 26 2024 · 5:30 PM ET † TNGXSALE Tango Therapeutics, Inc. View filing → $8.4M
2,700,000 sh across 3 lots
Exec Nov 6 2024
Filed Nov 8 2024 · 5:30 PM ET